Nodality Announces Presentations at 2010 ASH, Including Key Findings in Acute Myeloid Leukemia (AML) and Chronic Lymphocytic Leukemia (CLL)
South San Francisco, CA, November 29, 2010Nodality, Inc., a biotechnology company focused on the development of next generation highly predictive tests in cancer and autoimmune disease, today announced presentation of promising data related to the application of the company's novel, proprietary technology, Single Cell Network Profiling (SCNP) in hematologic malignancies. SCNP measures the activation levels of signaling networks at the single cell level by measuring the effects of multiple modulators, including drugs, on signaling pathways. This unique functional approach allows for the identification of the underlying heterogeneity in individual patient disease biology and enables efficient classification of patients into therapeutically relevant disease sub-populations by associating cell signaling with the pathogenesis of cancer.
Presented abstracts highlighting the clinical application of SCNP in patients with acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL) were presented at the recent 52nd annual meeting of the American Society of Hematology (ASH) in Orlando, Florida:
AML Abstracts
- Abstract No. 2695: Single-cell Network Profiling (SCNP) signatures Independently Predict Response to Induction Therapy in Older Patients with Acute Myeloid Leukemia (AML)
- Abstract No. 2693: Specimen Source (BM or PB) Does Not Affect Proteomic Signaling in Patients with AML and Circulating Blasts
- Abstract No. 2739: Characterization of FLT3 Pathway Deregulation by Single Cell Network Profiling (SCNP) Stratifies AML Patients Beyond Molecular Profiling
- Abstract No. 954: Single Cell Network Profiling (SCNP) Signatures Predict Response to Induction Therapy and Relapse Risk in Pediatric Patients with AML: COG study POG-9421 (selected for oral presentation)
- Abstract No. 4843: Sample Cryopreservation Does Not Affect Functional Read Outs in SCNP Assays: Implications for BioMarker Development (published online-only on the ASH abstracts site)
CLL Abstracts
- Abstract No. 3586: Single Cell Network Profiling (SCNP) Assay Reveals B Cell Receptor Signaling Heterogeneity in the Context of ZAP-70 Expression in Patients with CLL
Signaling Pathways
- Abstract No. 2753: Single Cell Network Profiling as a Platform to Reveal Leukemia-Specific Signaling Signatures with Sensitivity to Kinase Inhibitor Therapies
- Abstract No. 4867: (SCNP) of IFN-α Signaling Pathways in PBMCs from Healthy Donors: Implications for Disease Characterization, Treatment Selection, and Drug Discovery (published online-only on the ASH abstracts site)
- Abstract No.4768: Cellular and Intracellular Network Characterization of Cytokine JAK/STAT Signaling in Whole Blood Across Multiple Healthy Individuals: Defining “Normal” (published online-only on the ASH abstracts site)
Nodality is a private, South San Francisco-based biotechnology company focused on improving the development and clinical use of therapeutics in cancer and autoimmune disease through the application of its proprietary Single Cell Network Profiling technology platform. Through its ability to functionally characterize cell signaling networks at the single cell level of resolution Nodality is committed to the biological characterization of individual patients to optimally match them with biologically-targeted treatments.
About Single Cell Network ProfilingSingle Cell Network Profiling (SCNP) is a proprietary technology licensed from Stanford University to characterize cell signalling networks in patients with cancer and autoimmune diseases. SCNP, by measuring functional signaling network behavior in single cells, has several advantages over other currently used molecular technologies. These include unprecedented insight into the presence and clinical meaning of cellular heterogeneity including the importance of rare cells such as drug-resistant and stem cells. As the technology has widespread application in both preclinical and clinical drug development, Nodality is also utilizing SCNP in collaboration with drug developers to decrease the time, cost, and risks of drug development.